Evidence map›Paper›PMID 38282968›Full record

ArticleBioactive materials2024

Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T-cell membrane coated polymeric nanoparticles.

Serkan Yaman, Harish Ramachandramoorthy, Priyanka Iyer, Uday Chintapula, Tam Nguyen, Manoj Sabnani, Tanviben Kotadia, Soroush Ghaffari, Laurentiu M Pop, Raquibul Hannan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Biomimetic materials for medical applications.Chinese medical journal · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Serkan YamanDepartment of Bioengineering, University of Texas at Arlington, TX, USA.
Harish RamachandramoorthyDepartment of Bioengineering, University of Texas at Arlington, TX, USA.
Priyanka IyerDepartment of Bioengineering, University of Texas at Arlington, TX, USA.
Uday ChintapulaDepartment of Bioengineering, University of Texas at Arlington, TX, USA.
Tam NguyenDepartment of Bioengineering, University of Texas at Arlington, TX, USA.
Manoj SabnaniDepartment of Biology, University of Texas at Arlington, TX, USA.
Tanviben KotadiaDepartment of Biology, University of Texas at Arlington, TX, USA.
Soroush GhaffariDepartment of Kinesiology, University of Texas at Arlington, Arlington, TX, USA.
Laurentiu M PopDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, TX, USA.
Raquibul HannanDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, TX, USA.
Jon A WeidanzDepartment of Bioengineering, University of Texas at Arlington, TX, USA.
Kytai T NguyenDepartment of Bioengineering, University of Texas at Arlington, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell membrane-derived nanoparticles (NPs) have recently gained popularity due to their desirable features in drug delivery such as mimicking properties of native cells, impeding systemic clearance, and altering foreign body responses. Besides NP technology, adoptive immunotherapy has emerged due to its promise in cancer specificity and therapeutic efficacy. In this research, we developed a biomimetic drug carrier based on chimeric antigen receptor (CAR) transduced T-cell membranes. For that purpose, anti-HER2 CAR-T cells were engineered via lentiviral transduction of anti-HER2 CAR coding lentiviral plasmids. Anti-HER2 CAR-T cells were characterized by their specific activities against the HER2 antigen and used for cell membrane extraction. Anti-cancer drug Cisplatin-loaded poly (D, l-lactide-

Indexed as

Cancer chemotherapyCAR-T cellsMembrane-based drug deliveryNanoparticles

Identifiers

PMID38282968
PMCPMC10821609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.